UNCY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Unicycive Therapeutics Inc (UNCY) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The technical indicators show no clear upward momentum, and there are no strong proprietary trading signals or recent positive news catalysts. While analysts maintain a speculative buy rating with high price targets, the stock's current technical weakness and lack of immediate catalysts suggest holding off for now.
The MACD histogram is negative and expanding, indicating bearish momentum. RSI is at 34.728, which is neutral but close to oversold territory. Moving averages are converging, showing no clear trend. The stock is trading near its support level of 6.751, with resistance at 7.309. Overall, the technical indicators suggest a weak trend with no immediate bullish signals.
Analysts maintain speculative buy ratings with high price targets, citing potential FDA approval of oxylanthanum carbonate by June 29, which could address a $1.5B market.
The company has sufficient cash reserves to fund operations into 2027, ensuring stability for the near term.
The stock has shown a regular market decline of -2.84% and no significant upward momentum in technical indicators.
No recent news or event-driven catalysts to drive immediate price action.
Hedge funds and insiders remain neutral, with no significant trading trends.
No financial data available for analysis. However, the company reported a cash balance of $54.9M as of March 30, 2026, which is expected to fund operations into 2027.
Analysts maintain a speculative buy rating with price targets ranging from $15 to $40. Recent updates reflect adjustments for higher operating expenses and share count but remain optimistic about the company's drug pipeline and upcoming FDA approval.
